All Stories

  1. Single-nucleus multiomics reveals the disrupted regulatory programs in three brain regions of sporadic early-onset Alzheimer’s disease
  2. Genetic overlap between Alzheimer’s disease and immune-mediated diseases: an atlas of shared genetic determinants and biological convergence
  3. Genetic overlap between Alzheimer's disease and immune-mediated diseases: An atlas of shared genetic determinants and biological convergence
  4. GRPa-PRS: A risk stratification method to identify genetically-regulated pathways in polygenic diseases
  5. Improving drug development in precision psychiatry by ameliorating cognitive biases
  6. The kynurenine pathway in Alzheimer's disease: a meta-analysis of central and peripheral levels
  7. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a systematic review and meta-analysis of cerebrospinal fluid studies
  8. A single-cell atlas of the human brain in Alzheimer’s disease and its implications for personalized drug repositioning
  9. Fostering precision psychiatry through bioinformatics
  10. Treatment-resistant bipolar depression: concepts and challenges for novel interventions
  11. The Greater Houston Area Bipolar Registry—Clinical and Neurobiological Trajectories of Children and Adolescents With Bipolar Disorders and High-Risk Unaffected Offspring
  12. C-Reactive Protein and the Uncinate Fasciculus in Anhedonia and Depression
  13. Lower Reward Responsiveness is Associated With Lifetime Suicide Attempt in Children and Adolescents With Bipolar Disorders
  14. The Kynurenine Pathway in Major Depressive Disorder, Bipolar Disorder, and Schizophrenia: A Large Meta-Analysis
  15. The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies
  16. P.757 Antidepressant treatment decreases IL-6, IL-10 and serum cortisol in major depressive disorder: a meta-analysis of randomized controlled trials
  17. Precision psychiatry with immunological and cognitive biomarkers: a multi-domain prediction for the diagnosis of bipolar disorder or schizophrenia using machine learning
  18. Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders
  19. Editorial: Back to the Future: On the Road Towards Precision Psychiatry
  20. Mindfulness-based stress reduction for fibromyalgia: A step closer to precision psychiatry?
  21. Are remitted affective disorders and familial risk of affective disorders associated with metabolic syndrome, inflammation and oxidative stress? – a monozygotic twin study
  22. Applying biomarkers in psychiatry: Paving the way towards precision psychiatry
  23. Innate Immune Cells and C-Reactive Protein in Acute First-Episode Psychosis and Schizophrenia: Relationship to Psychopathology and Treatment
  24. Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity – a consensus of the Biomarkers Task Force from the WFSBP
  25. P.4.08 Metabolic syndrome, inflammation and oxidative stress as potential risk factors for affective disorders – a twin study
  26. Mapping risk factors for depression across the lifespan: An umbrella review of evidence from meta-analyses and Mendelian randomization studies
  27. Treatment of neurocognitive symptoms in unipolar depression: A systematic review and future perspectives
  28. The renin–angiotensin system: a possible new target for depression
  29. Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials
  30. The effect of N-acetylcysteine (NAC) on human cognition – A systematic review
  31. Relationship between depression and frailty in older adults: A systematic review and meta-analysis
  32. Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis
  33. Staging in bipolar disorder: one step closer to precision psychiatry
  34. Homocysteine as a peripheral biomarker in bipolar disorder: A meta-analysis
  35. 338. Enabling Precision Psychiatry through ‘omics’: From Biomarkers to Biological Pathways
  36. 980. Insulin is a State Biomarker in Major Depressive Disorder: A Systematic Review and Meta-Analysis
  37. Oxidative stress and frailty: A systematic review and synthesis of the best evidence
  38. The new field of ‘precision psychiatry’
  39. The Placebo and Nocebo Phenomena: Their Clinical Management and Impact on Treatment Outcomes
  40. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies
  41. Depression in cancer: The many biobehavioral pathways driving tumor progression
  42. C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysis
  43. Affective temperaments and emotional traits are associated with a positive screening for premenstrual dysphoric disorder
  44. Statins for the treatment of depression: A meta-analysis of randomized, double-blind, placebo-controlled trials
  45. Angiotensin Converting Enzyme Inhibitors and Risk of Mood Disorders
  46. Bias in emerging biomarkers for bipolar disorder
  47. T helper 17 cells may drive neuroprogression in major depressive disorder: Proposal of an integrative model
  48. Leptin in bipolar disorder: A systematic review and meta-analysis
  49. N-Acetylcysteine in Depressive Symptoms and Functionality
  50. Cognitive remission: a novel objective for the treatment of major depression?
  51. Premenstrual Symptoms Screening Tool--Brazilian Portuguese Version
  52. Bias in Peripheral Depression Biomarkers
  53. Peripheral vascular endothelial growth factor as a novel depression biomarker: A meta-analysis
  54. Peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in bipolar disorder: a meta-analysis of 52 studies
  55. Effects of Depression and Serotonergic Antidepressants on Bone: Mechanisms and Implications for the Treatment of Depression
  56. Future Directions for Pharmacotherapies for Treatment-resistant Bipolar Disorder
  57. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications
  58. Serum triglycerides, but not cholesterol or leptin, are decreased in suicide attempters with mood disorders
  59. Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications
  60. Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis
  61. The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies
  62. Biomarkers in bipolar disorder: A positional paper from the International Society for Bipolar Disorders Biomarkers Task Force
  63. Maintenance N-acetyl cysteine treatment for bipolar disorder: A double-blind randomized placebo controlled trial
  64. Minimum 2-year follow up of sex reassignment surgery in Brazilian male-to-female transsexuals
  65. Reduced serum non-enzymatic antioxidant defense and increased lipid peroxidation in schizophrenic patients on a hypocaloric diet
  66. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: An open label trial
  67. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance
  68. Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance
  69. Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: A systematic review and meta-regression analysis
  70. Hypersalivation Associated with Olanzapine and Valproate Combination: A Case Report
  71. Improvement of schizophrenia with electroconvulsive therapy and serum brain-derived neurotrophic factor levels: Lack of association in a pilot study
  72. Increased neurotrophin-3 in drug-free subjects with bipolar disorder during manic and depressive episodes
  73. Validity of the Portuguese version of the Bipolar Depression Rating Scale
  74. Lack of Association Between Serum Brain-Derived Neurotrophic Factor Levels and Improvement of Schizophrenia Symptoms in a Double-Blind, Randomized, Placebo-Controlled Trial of Memantine as Adjunctive Therapy to Clozapine
  75. The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers
  76. Improvement of Negative and Positive Symptoms in Treatment-Refractory Schizophrenia
  77. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: A potential adjunctive tool for differential diagnosis
  78. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients
  79. Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder
  80. Serum brain-derived neurotrophic factor (BDNF) is not associated with response to electroconvulsive therapy (ECT): A pilot study in drug resistant depressed patients
  81. Feasibility of Treating Swine Manure in an Anaerobic Sequencing Batch Biofilm Reactor With Mechanical Stirring
  82. Evaluation of the treadmill stress testing for risk stratification after acute myocardial infarction